Abstract
The risk of developing an infection in patients with genitourinary tract malignancy arise from a host of factors such as: (1) tumor encroachment and invasion of adjacent structures; (2) tumor necrosis; (3) complications arising from antineoplastic chemotherapy; (4) early and late effects of abdomiopelvic radiation therapy; (5) surgical tumor excision and removal of internal organs; (6) structural abnormalities resulting from surgical diversion procedures; and (7) other causes that disrupt protective barriers in urinary and female reproductive tract. The spectrum of causative organisms most frequently arise from patients’ endogenous microflora. The vagina, lower urinary and intestinal tract colonization with bacteria and yeast serves as important sources for infection. The normal aerobic and anaerobic vaginal bacterial flora may be altered in patients undergoing antineoplastic therapy. Among factors that influence changes in colonization includes, hormonal dysfunction, frequent exposure to broad-spectrum antimicrobial agents, antineoplastic therapy, hospitalization, and instrumentization. Peritonitis, intraabdominal abscess, complicated urinary tract infection, surgical wound infection, skin and soft tissue infection such as cellulitis, necrotizing fasciitis, clostridial myonecrosis, and septic pelvic thrombophlebitis are important infectious complications encountered in patients with genitourinary tract malignancies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Safdar A, Armstrong D. Infections in patients with neoplastic diseases. In: Grenvik M, Ayers SM, Holbrook PR, Shoemaker WC, editors. Textbook of critical care. 4th ed. Philadelphia: W.B. Saunders; 2000. p. 715–26.
Safdar A, Armstrong D. Infectious morbidity in critically ill patients with cancer. Crit Care Clin. 2001;17:531–70.
Evaldson G, Heimdahl A, Kager L, et al. The normal human anaerobic microflora. Scand J Infect Dis. 1982;35:9–15.
Rolston KVI, Bodey GP, Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis. 2007;45:228–33.
Barton DPJ, Fiorica JV, Hoffman MS, et al. Cervical cancer and tubo-ovarian abscesses: a report of three cases. J Reprod Med. 1993;38:561–4.
Imachi M, Tanaka S, Ishikawa S, et al. Spontaneous perforation of pyometra presenting as generalized peritonitis in a patient with cervical cancer. Gynecol Oncol. 1993;50:384–8.
Protopappas AG, Diakomanolis ES, Milingos SD, et al. Tubo-ovarian abscess in postmenopausal women: gynecological malignancy until proven otherwise. Eur J Obstet Gynecol Reprod Biol. 2004;114:203–9.
Inagaki J, Rodriguez V, Bodey GP. Causes of death in cancer patients. Cancer. 1974;33:568–73.
Iatrakis G, Sakellaropoulos G, Georgoulias N, et al. Gynecologic cancer and surgical infectious morbidity. Clin Exp Obstet Gynecol. 1998;25:36–7.
Chang HK, Lo KY, Chiang HS. Complications of urinary diversion after pelvic exenteration for gynecological malignancy. Int Urogynecol J. 2000;11:358–60.
Wydra D, Emerich J, Sawicki S, et al. Major complications following exenteration in cases of pelvic malignancies: a 10-year experience. World J Gastroenterol. 2006;12:1115–9.
Matar MJ, Safdar A, Rolston KV. Relationship of colonization with vancomycin-resistant enterococci and risk of systemic infection in patients with cancer. Clin Infect Dis. 2006;42:1506–7.
Gould N, Kamelle S, Tillmanns T, et al. Predictors of complications after inguinal lymphadenopathy. Gynecol Oncol. 2001;82:329–32.
Safdar A, Rolston KV. Stenotrophomonas maltophilia: changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007;45:1602–9.
Safdar A, Rodriguez GH, Balakrishnan M, et al. Changing trends in etiology of bacteremia in patients with cancer. Eur J Clin Microbiol Infect Dis. 2006;25:522–6.
Han XY, Kamana M, Rolston KV. Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol. 2006;44:160–5.
Green JA, Kirwan JM, Tierney JF. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix. Lancet. 2001;385:781–6.
Yessaian A, Magistris A, Burger RA, et al. Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage 1B2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecol Oncol. 2004;94:61–6.
Jurado M, Martinez-Monge R, Garcia-Foncillas J, et al. Pilot study of concurrent cisplatin, 5-fluorouracil, and external beam radiotherapy prior to radical surgery +/− intraoperative electron beam radiotherapy in locally advanced cervical cancer. Gynecol Oncol. 1999;74:30–7.
Micha JP, Goldstein BH, Rettenmaier MA, et al. Pelvic radiation necrosis and osteomyelitis following chemoradiation for advanced stage vulvar and cervical carcinoma. Gynecol Oncol. 2006;101:349–52.
Anatoliotaki A, Valatas V, Mantadakis E, et al. Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome. Infection. 2004;32:65–71.
Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis. 1997;25:247–59.
Zahar JR, Farhat H, Chachaty E, et al. Incidence and clinical significance of anaerobic bacteremia in cancer patients: a 6-year retrospective study. Clin Microbiol Infect. 2005;11:724–9.
Fainstein V, Elting LS, Bodey GP. Bacteremia caused by non-sporulating anaerobes in cancer patients – a 12-year experience. Medicine (Baltimore). 1989;68:151–62.
Wynne JW, Armstrong D. Clostridial septicemia. Cancer. 1972;29:215–21.
Safdar A. Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections. Bone Marrow Transplant. 2006;38:327–37.
Raad I, Hachem R, Hanna H, et al. Sources and outcome of bloodstream infections in cancer patients: the role of central venous catheters. Eur J Clin Microbiol Infect Dis. 2007;26:549–56.
Raad I, Hanna H, Jiang Y, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007;51:1656–60.
Strecker EP, Heber R, Boos I, et al. Preliminary experience with locoregional intraarterial chemotherapy of uterine cervical or endometrial cancer using the peripheral implantable port system (PIPS): a feasibility study. Cardiovasc Intervent Radiol. 2003;26:118–22.
Sakuragi N, Nakajima A, Nomura E, et al. Complications related to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma. Gynecol Oncol. 2000;79:420–3.
Roybal JJ, Feliberti EC, Rouse L, et al. Pump removal in infected patients with hepatic chemotherapy pumps: when is it necessary? Am Surg. 2006;72:880–4.
Prasad KN, Pradhan S, Datta NR. Urinary tract infection in patients of gynecological malignancies undergoing external pelvic radiotherapy. Gynecol Oncol. 1995;57:380–2.
Roos EJ, Van Eijkeren MA, Boon TA, et al. Pelvic exenteration as treatment of recurrent or advanced gynecologic and urologic cancer. Int J Gynecol Cancer. 2005;15:624–9.
Velasco E, Thuler LC, Martins CA, et al. Risk factors for infectious complications after abdominal surgery for malignant disease. Am J Infect Control. 1996;24:1–6.
Brooker DC, Savage JE, Twiggs LB, et al. Infectious morbidity in gynecologic cancer. Am J Obstet Gynecol. 1987;156:513–20.
Morgan LS, Daly JW, Monif GR. Infectious morbidity associated with pelvic exenteration. Gynecol Oncol. 1980;10:318–28.
Ledger WJ, Gee C, Lewis WP. Guidelines for antibiotic prophylaxis in gynecology. Am J Obstet Gynecol. 1975;121:1038–45.
Hemsell DL, Johnson ER, Hemsell PG, et al. Cefazolin is inferior to cefotetan as single-dose prophylaxis for women undergoing elective total abdominal hysterectomy. Clin Infect Dis. 1995;20:677–84.
Hemsell DL, Bernstein SG, Bawdon RE, et al. Preventing major operative site infection after radical abdominal hysterectomy and pelvic lymphadenectomy. Gynecol Oncol. 1989;35:55–60.
Orr Jr JW, Shingleton HM, Hatch KD, et al. Correlation of perioperative morbidity and conization to radical hysterectomy interval. Obstet Gynecol. 1982;59:726–31.
Berkeley AS, Orr JW, Cavanagh D, et al. Comparative effectiveness and safety of cefotetan and cefoxitin as prophylactic agents in patients undergoing abdominal or vaginal hysterectomy. Am J Surg. 1988;155:81–5.
Mann Jr WJ, Orr JW, Shingleton HM, et al. Perioperative influences on infectious morbidity in radical hysterectomy. Gynecol Oncol. 1981;11:207–12.
Gussman D, Riva J, Carlson Jr JA. Prophylaxis for radical hysterectomy. Infect Surg. 1987;6:55.
Rosenshein NB, Ruth JC, Villar J, et al. A prospective randomized study of doxycycline as a prophylactic antibiotic in patients undergoing radical hysterectomy. Gynecol Oncol. 1983;15:201–6.
Marsden DE, Cavanagh D, Wisniewski BJ, et al. Factors affecting the incidence of infectious morbidity after radical hysterectomy. Am J Obstet Gynecol. 1985;152:817–21.
Sevin BU, Ramos R, Lichtinger M, et al. Antibiotic prevention of infections complicating radical abdominal hysterectomy. Obstet Gynecol. 1984;64:539–45.
Micha JP, Kucera PR, Birkett JP, et al. Prophylactic mezlocillin in radical hysterectomy. Obstet Gynecol. 1987;69:251–4.
Sevin BU, Ramos R, Gerhardt RT, et al. Comparative efficacy of short-term versus long-term cefoxitin prophylaxis against postoperative infection after radical hysterectomy: a prospective study. Obstet Gynecol. 1991;77:729–34.
Shapiro M, Schoenbaum SC, Tager IB, et al. Benefit-cost analysis of antimicrobial prophylaxis in abdominal and vaginal hysterectomy. JAMA. 1983;249:1290–4.
van Lindert AC, Giltaij AR, Derksen MD, et al. Single-dose prophylaxis with broad-spectrum penicillins (piperacillin and mezlocillin) in gynecologic oncological surgery, with observation on serum and tissue concentrations. Eur J Obstet Gynecol Reprod Biol. 1990;36:137–45.
Shapiro M, Munoz A, Tager IB, et al. Risk factors for infection at the operative site after abdominal or vaginal hysterectomy. N Engl J Med. 1982;307:1661–6.
Contant CM, Hop WC, van’t Sant HP, et al. Mechanical bowel preparation for elective colorectal surgery: a multicenter randomized trial. Lancet. 2008;370:2112–7.
Braverman J, Adachi A, Lev-Gur M, et al. Spontaneous clostridia gas gangrene of uterus associated with endometrial malignancy. Am J Obstet Gynecol. 1987;156:1205–7.
Douvier S, Nabholtz JM, Friedman S, et al. Infectious pneumoperitoneum as an uncommon presentation of endometrial carcinoma: report of two cases. Gynecol Oncol. 1989;33:392–4.
Weinstein WM, Onderdonk AB, Bartlett JG, et al. Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun. 1974;10:1250–5.
Henderson W. Synergistic bacterial gangrene abdominal hysterectomy. Obstet Gynecol. 1977;49:24S.
Bouma J, Dankert J. Recurrent acute leg cellulitis in patients after radical vulvectomy. Gynecol Oncol. 1988;29:50–7.
Hunt TK, Rabkin J, von Smitten K. Effects of edema and anemia on wound healing and infection. Curr Stud Hematol Blood Transfus. 1986;53:101–13.
Bahary CM, Joel-Cohen SJ, Neri A. Necrotizing fasciitis. Obstet Gynecol. 1977;50:633–7.
Wilson B. Necrotizing fascitits. Am Surg. 1952;18:416.
Husseinzadeh N et al. Spontaneous occurrence of synergistic bacterial gangrene following external pelvic irradiation. Obstet Gynecol. 1984;63:859–62.
Hoffman MS, Turnquist D. Necrotizing fasciitis of the vulva during chemotherapy. Obstet Gynecol. 1989;74:483–4.
Roberts D. Necrotizing fasciitis of the vulva. Am J Obstet Gynecol. 1987;157:568.
Fisher JR, Conway MJ, Takeshita RT, et al. Necrotizing fasciitis. Importance of roentgenographic studies for soft-tissue gas. JAMA. 1979;241:803–6.
Altmeier WA. Gas gangrene. Surg Gynecol Obstet. 1947;84:504.
Pelletier JP, Plumbley JA, Rouse EA, Cina SJ. The role of Clostridium septicum in paraneoplastic sepsis. Arch Pathol Lab Med. 2000;124:353–6.
McNeeley Jr SG, Hopkins MP, Ehlerova B, et al. Infection on a gynecologic oncology service. Gynecol Oncol. 1990;37:183–7.
Miller C. Ligation or excision of the pelvic veins in the treatment of puerperal pyaemia. Surg Gynecol Obstet. 1917;25:431.
Twickler DM et al. Imaging of puerperal septic thrombophlebitis: prospective comparison of MR imaging, CT, and sonography. AJR Am J Roentgenol. 1997;169:1039–43.
Zerhouni EA, Barth KH, Siegelman SS. Demonstration of venous thrombosis by computed tomography. AJR Am J Roentgenol. 1980;134:753–8.
Schulman H, Zatuchni G. Pelvic thrombophlebitis in the puerperal and postoperative gynecology patient. Obscure fever as an indication for anticoagulant therapy. Am J Obstet Gynecol. 1964;90:1293.
Twickler DM, Setiawan AT, Evans RS, et al. Imaging of puerperal septic thrombophlebitis: prospective comparison of MR imaging, CT, and sonography. AJR Am J Roentgenol. 1997;169:1039–43.
Josey WE, Staggers Jr SR. Heparin therapy in septic pelvic thrombophlebitis: a study of 46 cases. Am J Obstet Gynecol. 1974;120:228–33.
Brown CE, Stettler RW, Twickler D, et al. Puerperal septic pelvic thrombophlebitis: incidence and response to heparin therapy. Am J Obstet Gynecol. 1999;181:143–8.
Lee AY et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–53.
Ruokonen E et al. Procalcitonin and neopterin as indicators of infection in critically ill patients. Acta Anaesthesiol Scand. 2002;46:398–404.
Hirschmann JV. Fever of unknown origin in adults. Clin Infect Dis. 1997;24:291–300. Quiz 301–2.
Acknowledgement
The authors are grateful to Drs. Donald Armstrong and Kent Sepkowitz of Memorial Sloan-Kettering Cancer Center for their contribution to this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Safdar, A., Markman, M. (2011). Management of Genitourinary Tract Infections. In: Safdar, A. (eds) Principles and Practice of Cancer Infectious Diseases. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-644-3_18
Download citation
DOI: https://doi.org/10.1007/978-1-60761-644-3_18
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-643-6
Online ISBN: 978-1-60761-644-3
eBook Packages: MedicineMedicine (R0)